Around 1,000 people with HER2-low advanced breast cancer can now be offered Enhertu after NICE recommended it for routine NHS use.

People with obsessive-compulsive disorder (OCD) and body dysmorphic disorder (BDD) could be identified earlier and offered more appropriate treatment under draft NICE guidance published today.

Learn how NICE Advice’s system engagement service helps life sciences companies spot NHS adoption barriers before they become roadblocks.